These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

849 related items for PubMed ID: 18261784

  • 1. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J, Rose P.
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH, Bailey CL, Savage J, Young JA.
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [Abstract] [Full Text] [Related]

  • 3. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ, Park JY, Kim DY, Kim JH, Kim YM, Nam JH, Kim YT.
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [Abstract] [Full Text] [Related]

  • 4. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL.
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [Abstract] [Full Text] [Related]

  • 5. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [Abstract] [Full Text] [Related]

  • 6. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [Abstract] [Full Text] [Related]

  • 9. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 10. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
    Matulonis UA, Krag KJ, Krasner CN, Atkinson T, Horowitz NS, Lee H, Penson RT.
    Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
    [Abstract] [Full Text] [Related]

  • 11. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF, Liu FY, Chen FJ, Feng YL.
    Ai Zheng; 2007 Apr 01; 26(4):431-4. PubMed ID: 17430668
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M.
    Gynecol Oncol; 2002 Apr 01; 85(1):129-35. PubMed ID: 11925132
    [Abstract] [Full Text] [Related]

  • 15. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 01; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 16. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA, Hellenic Cooperative Oncology Group study.
    Eur J Cancer; 2008 Oct 01; 44(15):2169-77. PubMed ID: 18691879
    [Abstract] [Full Text] [Related]

  • 17. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA.
    BMC Cancer; 2006 Sep 25; 6():228. PubMed ID: 16999858
    [Abstract] [Full Text] [Related]

  • 18. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
    Higgins RV, Naumann RW, Gardner J, Hall JB.
    Gynecol Oncol; 1999 Dec 25; 75(3):464-7. PubMed ID: 10600308
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Rose PG, Smrekar M, Fusco N.
    Gynecol Oncol; 2005 Feb 25; 96(2):296-300. PubMed ID: 15661211
    [Abstract] [Full Text] [Related]

  • 20. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B, Høgdall C, Hansen HH, Engelholm SA.
    Gynecol Oncol; 2001 Oct 25; 83(1):128-34. PubMed ID: 11585424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.